Metabolic reprogramming and partial acquisition of cancer stem cell-like phenotype in human umbilical cord-mesenchymal stem cells under hypoxia

This study reveals that culturing human umbilical cord mesenchymal stem cells (hUC-MSCs) under hypoxia induces metabolic reprogramming and a partial cancer stem cell-like phenotype with accelerated proliferation, raising significant safety concerns regarding their clinical application despite their enhanced therapeutic potential.

The Gist

The Big Idea: A "Super-Cell" That Might Be Too Super

Imagine you have a team of construction workers (Stem Cells) that you want to use to fix a broken building (a patient's injury). Scientists have long believed that if you put these workers in a low-oxygen environment (like a basement), they become more energetic, faster, and better at their job. This is especially true for workers harvested from the umbilical cord (hUC-MSCs).

However, this new study from Tohoku University asks a scary question: What if we made them too energetic?

The researchers found that when they put umbilical cord stem cells in a low-oxygen "basement" for two weeks, they didn't just get better at fixing things; they started acting like cancer cells. They grew so fast they outpaced actual cancer cells, and they started changing their internal machinery to look and act like "Cancer Stem Cells"—the tough, unkillable bosses of tumors.

---

The Experiment: The "Gym" vs. The "Basement"

The scientists took two types of construction workers:

1. Bone Marrow Workers (hBM-MSCs): These are the older, more traditional workers.
2. Umbilical Cord Workers (hUC-MSCs): These are the younger, more energetic workers.

They put both groups into two different environments for two weeks:

• The "Gym" (Normal Air/21% Oxygen): Where they usually work.
• The "Basement" (Low Oxygen/1% Oxygen): The hypoxic condition scientists love to use to boost performance.

They also brought in two "villains" for comparison: Glioblastoma (brain cancer) and Breast Cancer cells.

The Shocking Results

1. The Race for Speed

When the race started, the Umbilical Cord workers in the Basement went crazy.

• They grew so fast that they outran the actual cancer cells.
• While the cancer cells took about 23–24 hours to double in number, the Umbilical Cord workers in the basement did it in just 19 hours.
• The Analogy: Imagine a Ferrari (the cancer cell) and a Formula 1 car (the stem cell). You put the Ferrari in a garage, but you put the F1 car in a wind tunnel. Suddenly, the F1 car is driving faster than the Ferrari ever could.

Meanwhile, the Bone Marrow workers didn't change much. Whether they were in the gym or the basement, they kept working at their normal, slow pace. They didn't get the "super boost."

2. The Internal Makeover (Metabolic Reprogramming)

Why did the Umbilical Cord workers get so fast? The scientists looked inside their "engines" (genes).

• They found that the low oxygen triggered a massive metabolic reprogramming.
• The Analogy: It's like the workers suddenly decided to stop eating sandwiches and started eating pure, high-octane jet fuel. They switched their internal factory to produce massive amounts of cholesterol and fats.
• Why? Because cancer cells do this to build new cell membranes quickly so they can multiply. The Umbilical Cord workers started building their own "armor" and "fuel tanks" just like a tumor would.

3. The "Boss" Switch (Cancer Stem Cell Traits)

Not only did they speed up, but they also started wearing the "uniform" of a Cancer Stem Cell.

• They turned on genes usually found in tumors (like the Wnt and Hedgehog pathways).
• They turned on "survival switches" that make them hard to kill (apoptosis resistance).
• The Analogy: These workers didn't just get faster; they started acting like the gang leaders of a criminal organization. They became harder to stop, harder to kill, and obsessed with self-replication.

4. The Lost Compass (Homing Failure)

The final twist was about where these cells went.

• When injected into mice with brain injuries, the normal workers (in the gym) managed to find their way to the injury site, though not perfectly.
• The super-fast basement workers? They got lost. They barely showed up at the injury site.
• The Analogy: The normal workers had a GPS that led them to the broken building. The super-fast workers were so focused on running and building their own empire that they forgot where they were supposed to go. They got stuck in the lungs instead of helping the brain.

---

The Conclusion: A Warning Label

The study concludes with a serious warning for the medical world.

For years, doctors have been excited about using low-oxygen stem cells because they think it makes them "superheroes." This paper says: "Be careful. You might be creating a monster."

While these Umbilical Cord stem cells are amazing, putting them in a low-oxygen environment might turn them into something that grows uncontrollably (like a tumor) and loses its ability to find the injury.

The Takeaway:
Before we start using these "super-charged" cells in humans, we need to make sure we aren't accidentally giving patients a treatment that acts more like a cancer than a cure. The "Basement" might be too dangerous for these specific workers.

Technical Summary

1. Problem Statement

Mesenchymal stem cells (MSCs), particularly those derived from human umbilical cord (hUC-MSCs), are widely investigated for clinical therapies due to their regenerative potential and low tumorigenicity. There is a growing trend to culture MSCs under hypoxic conditions (low oxygen) to enhance their therapeutic efficacy, stemness, and proliferation. However, the biological consequences of prolonged hypoxia on hUC-MSCs compared to bone marrow-derived MSCs (hBM-MSCs) remain unclear. Specifically, there is a lack of data regarding whether hypoxic culture induces metabolic reprogramming or malignant transformation traits (such as cancer stem cell-like phenotypes) that could compromise safety.

2. Methodology

The study employed a comparative approach using human hUC-MSCs and hBM-MSCs (three independent batches each, passage 6).

• Culture Conditions:
  • Normoxia: 21% O₂.
  • Hypoxia: 1% O₂ (for 2 weeks).
  • Controls: Human malignant glioblastoma cells (U251) and breast carcinoma cells (MCF-7) were used as benchmarks for proliferation rates.
• Proliferation Assays:
  • Cells were seeded at 2,500 cells/cm².
  • Cell counts were performed manually over 7 days.
  • Population Doubling Time (PDT) was calculated during the exponential growth phase (days 6–7).
• Transcriptomic Analysis (RNA-seq):
  • RNA was extracted from Hypo-hUC-MSCs and Hypo-hBM-MSCs.
  • Differentially Expressed Genes (DEGs) were identified using DESeq2 (threshold: |log2FC| ≥ 1, adjusted p < 0.001).
  • Functional enrichment analysis was conducted via Metascape to identify pathways related to metabolism, proliferation, and hypoxia response.
• In Vivo Homing Study:
  • A mouse model of traumatic brain injury (TBI) was induced via freezing injury.
  • 1 × 10⁵ Akaluc-labeled Normo-hUC-MSCs or Hypo-hUC-MSCs were injected intravenously 7 days post-injury.
  • Cell homing to the brain and accumulation in the lungs were quantified 3 days post-injection using bioluminescence imaging (IVIS).

3. Key Results

A. Proliferation Dynamics

• Hypo-hUC-MSCs: Exhibited an extremely accelerated proliferation rate, surpassing even cancer cell lines.
  • By Day 7, cell counts reached 146.4 ± 8.3 × 10³, significantly higher than U251 (57.7 × 10³) and MCF-7 (81.3 × 10³).
  • PDT: Hypo-hUC-MSCs had a PDT of 19.1 ± 1.0 hours, which was significantly shorter than U251 (23.9 hrs) and MCF-7 (22.9 hrs).
• Hypo-hBM-MSCs: Showed no significant difference in proliferation between normoxia and hypoxia. Their growth remained slower than cancer cells and comparable to normoxic controls.
• Morphology: Hypo-hUC-MSCs appeared smaller and rounder compared to normoxic controls, whereas hBM-MSC morphology remained largely unchanged.

B. Transcriptomic Reprogramming

Comparing Hypo-hUC-MSCs to Hypo-hBM-MSCs revealed distinct gene expression profiles:

• Metabolic Reprogramming in Hypo-hUC-MSCs:
  • Cholesterol Biosynthesis: Significant upregulation of the entire pathway, including IDH1, HMGCS1, HMGCR, IDI1, FDFT1, SQLE, and TM7SF2.
  • Fatty Acid Metabolism: Upregulation of SCD, ELOVL2, and ACSL3.
• Cancer Stem Cell (CSC)-Like Phenotype in Hypo-hUC-MSCs:
  • Signaling Pathways: Upregulation of Wnt (FZD2) and Hedgehog (GLI1) pathway components.
  • Proliferation Drivers: Increased expression of KSR1, PLAC1, SKP2, and CDK15.
  • Stress/Apoptosis Resistance: Elevated levels of anti-apoptotic chaperone HYOU1 and lipid signaling kinase PIK3C2B.
• Hypoxic Response in hBM-MSCs:
  • Hypo-hBM-MSCs showed higher expression of HIF1A (approx. 2x higher than Hypo-hUC-MSCs) and genes related to canonical hypoxia responses and environmental adaptation, but lacked the metabolic and proliferative "explosion" seen in hUC-MSCs.

C. In Vivo Homing Efficiency

• Normo-hUC-MSCs: Showed faint but detectable homing signals to the TBI site in the brain.
• Hypo-hUC-MSCs: Demonstrated significantly reduced homing to the injured brain compared to normoxic controls (p < 0.01).
• Lung Sequestration: Both groups showed high accumulation in the lungs with no statistical difference, indicating that hypoxia did not improve systemic distribution to the injury site.

4. Key Contributions

1. Differential Response to Hypoxia: The study establishes that hUC-MSCs and hBM-MSCs respond fundamentally differently to hypoxic culture. While hBM-MSCs maintain a stable phenotype, hUC-MSCs undergo drastic changes.
2. Identification of Malignant-Like Traits: The authors provide evidence that 2 weeks of hypoxia induces a partial acquisition of cancer stem cell-like traits in hUC-MSCs, characterized by:
   • Proliferation rates exceeding those of established cancer cell lines.
   • Metabolic reprogramming toward cholesterol and fatty acid synthesis (similar to tumor microenvironments).
   • Activation of self-renewal pathways (Wnt/Hedgehog) and apoptosis resistance.
3. Safety Warning: The study challenges the assumption that hypoxic culture is universally beneficial. It highlights a specific safety risk where hypoxic hUC-MSCs may lose their "safe" non-tumorigenic profile and gain aggressive proliferative capabilities.
4. Functional Consequence: The study links these molecular changes to a functional deficit: the loss of homing ability to injury sites in vivo.

5. Significance and Implications

• Clinical Safety: The findings suggest that the use of hypoxia-cultured hUC-MSCs in clinical trials requires rigorous re-evaluation. The "accelerated proliferation" observed is not merely a therapeutic benefit but a potential safety hazard resembling oncogenic transformation.
• Mechanistic Insight: The paper elucidates a mechanism where hypoxia drives lipid metabolism reprogramming (cholesterol/fatty acids), potentially altering membrane lipid rafts to hyper-activate survival and proliferation signaling (Wnt/Hedgehog/PI3K).
• Future Directions: The authors conclude that while hypoxic MSCs are popular for therapy, the specific combination of hUC source + hypoxic culture may carry unique risks. Comprehensive safety investigations, including long-term tumorigenicity studies in animal models, are necessary before clinical application.

Conclusion: While hypoxia is often touted to enhance MSC potency, this study demonstrates that for hUC-MSCs, it may induce a dangerous phenotype characterized by cancer-like proliferation, metabolic reprogramming, and reduced therapeutic homing, necessitating a cautious approach to their clinical translation.